Penumbra, Inc. (NYSE:PEN) Shares Purchased by Barclays PLC

Barclays PLC raised its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 65.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,796 shares of the company's stock after acquiring an additional 11,771 shares during the quarter. Barclays PLC owned approximately 0.08% of Penumbra worth $7,076,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PEN. Sanctuary Advisors LLC purchased a new position in Penumbra in the 3rd quarter valued at $367,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Penumbra in the third quarter valued at about $6,995,000. Tidal Investments LLC lifted its stake in shares of Penumbra by 2.7% in the third quarter. Tidal Investments LLC now owns 5,008 shares of the company's stock worth $973,000 after buying an additional 130 shares in the last quarter. Franklin Resources Inc. boosted its position in Penumbra by 8.2% during the third quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock worth $67,473,000 after acquiring an additional 24,091 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Penumbra by 160.8% during the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company's stock valued at $106,000 after acquiring an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Stock Up 0.8 %

Penumbra stock traded up $2.25 during mid-day trading on Friday, reaching $300.50. 608,778 shares of the company's stock were exchanged, compared to its average volume of 424,593. The company has a fifty day moving average of $276.99 and a 200-day moving average of $254.78. The company has a market cap of $11.64 billion, a P/E ratio of 883.82, a P/E/G ratio of 2.83 and a beta of 0.56. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.66 by $0.17. The firm had revenue of $324.14 million during the quarter, compared to analysts' expectations of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Buying and Selling

In related news, CFO Maggie Yuen sold 2,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $286.00, for a total transaction of $572,000.00. Following the completion of the transaction, the chief financial officer now owns 15,243 shares in the company, valued at approximately $4,359,498. The trade was a 11.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $300.01, for a total value of $180,006.00. Following the completion of the transaction, the executive vice president now directly owns 66,159 shares in the company, valued at $19,848,361.59. This trade represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 128,446 shares of company stock worth $35,959,193 over the last 90 days. 5.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

PEN has been the topic of several recent research reports. Bank of America initiated coverage on Penumbra in a report on Friday, March 14th. They set a "buy" rating and a $320.00 target price on the stock. Canaccord Genuity Group upped their price objective on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Morgan Stanley lifted their target price on shares of Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 19th. Stifel Nicolaus set a $318.00 price target on shares of Penumbra and gave the company a "buy" rating in a research note on Thursday. Finally, Wells Fargo & Company raised their price target on shares of Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.